不同比例头孢哌酮/舒巴坦治疗肾盂肾炎患者的比较。

Comparison of different ratios of cefoperazone/sulbactam in patients with pyelonephritis.

作者信息

Jiang Weizhong, Cai Lili

机构信息

Weizhong Jiang, Department of Nephrology, Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, Huzhou, Zhejiang Province, 313000 P.R. China.

Lili Cai, Department of Nephrology, Huzhou Traditional Chinese Medicine Hospital, Affiliated to Zhejiang Chinese Medical University, Huzhou, Zhejiang Province, 313000 P.R. China.

出版信息

Pak J Med Sci. 2023 Jan-Feb;39(1):55-59. doi: 10.12669/pjms.39.1.6850.

DOI:10.12669/pjms.39.1.6850

PMID:36694775

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9843024/

Abstract

OBJECTIVE

To compare the clinical efficacy of different ratios of cefoperazone/sulbactam in the treatment of patients with pyelonephritis.

METHODS

In this retrospective study clinical records of patients with pyelonephritis treated in Huzhou Traditional Chinese Medicine Hospital from July 2020 to July 2021 were collected,. It included 55 patients who received cefoperazone/sulbactam 2:1 treatment (Control group) and 57 patients who received 1 cefoperazone/sulbactam 1:1 treatment (Observation group). Clinical response, inflammatory reaction and bacterial clearance were compared between the two groups.

RESULTS

The levels of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-8 (IL-8) and leukocyte count (WBC) in the observation group were lower than those in the control group (<0.05). The total efficacy of the Observation-group was 92.98%, higher than 80.00% of the control group (<0.05). Fifty-eight strains of bacteria were isolated from the Control-group and 59 strains from the Observation-group. The bacterial clearance rates were 65.52% (38/58) and 83.05% (49/59), respectively. The differences were statistically significant (<0.05).

CONCLUSIONS

The clinical efficacy of 1:1 ratio of cefoperazone/sulbactam in the treatment of patients with pyelonephritis was superior that of 2:1 ratio. This ratio allows to fully utilize the antibacterial effect of cefoperazone, with a significant decrease in inflammation markers and an improvement in bacterial clearance.

摘要

目的

比较不同配比的头孢哌酮/舒巴坦治疗肾盂肾炎患者的临床疗效。

方法

本回顾性研究收集了2020年7月至2021年7月在湖州市中医院接受治疗的肾盂肾炎患者的临床记录。其中55例患者接受头孢哌酮/舒巴坦2:1治疗（对照组），57例患者接受头孢哌酮/舒巴坦1:1治疗（观察组）。比较两组的临床反应、炎症反应及细菌清除情况。

结果

观察组C反应蛋白（CRP）、白细胞介素-6（IL-6）、白细胞介素-8（IL-8）水平及白细胞计数（WBC）均低于对照组（P<0.05）。观察组总有效率为92.98%，高于对照组的80.00%（P<0.05）。对照组分离出58株细菌，观察组分离出59株细菌。细菌清除率分别为65.52%（38/58）和83.05%（49/59），差异有统计学意义（P<0.05）。